MovDisordV3, Main, Exploration, bibRecord, 003441

Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication

Identifieur interne : 003441 ( Main/Exploration ); précédent : 003440; suivant : 003442

Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication

Auteurs : Angela Deutschl Nder [Allemagne] ; Friedrich Asmus [Allemagne] ; Elena Marelli [Allemagne] ; Thomas Klopstock [Allemagne] ; Thomas Gasser [Allemagne] ; Kai Bötzel [Allemagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-09.

RBID : ISTEX:F709477DA81BF6273D42B0F7D00924C11109FCA3

Descripteurs français

Pascal (Inist)
- Apomorphine, Ataxie optique, Chimiothérapie, Lévodopa, Nerf optique, Neuropathie nerf optique, Neuropathie optique, Parkinsonisme, Système nerveux pathologie, Voie orale.

English descriptors

KwdEn :
- Administration, Oral, Amantadine (administration & dosage), Antiparkinson Agents (administration & dosage), Apomorphine (administration & dosage), Chemotherapy, Combined Modality Therapy, Deep Brain Stimulation, Dose-Response Relationship, Drug, Drug Resistance, Drug Therapy, Combination, Humans, Hypokinesia (diagnosis), Hypokinesia (drug therapy), Infusions, Intravenous, Injections, Subcutaneous, Levodopa, Levodopa (administration & dosage), Middle Aged, Nervous system diseases, Neurologic Examination (drug effects), Optic Atrophy (diagnosis), Optic Atrophy (drug therapy), Optic ataxia, Optic nerve, Optic neuropathy, Oral administration, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinsonism, apomorphine, levodopa, optic nerve neuropathy.
MESH :
- chemical , administration & dosage : Amantadine, Antiparkinson Agents, Apomorphine, Levodopa.
- diagnosis : Hypokinesia, Optic Atrophy, Parkinson Disease.
- drug effects : Neurologic Examination.
- drug therapy : Hypokinesia, Optic Atrophy, Parkinson Disease.
- Administration, Oral, Combined Modality Therapy, Deep Brain Stimulation, Dose-Response Relationship, Drug, Drug Resistance, Drug Therapy, Combination, Humans, Infusions, Intravenous, Injections, Subcutaneous, Middle Aged.

Abstract

Two patients presented with the cardinal symptoms of Parkinson's disease (PD), which had developed slowly and progressively. One patient underwent brain imaging of the dopaminergic system, the results of which were compatible with PD. However, both patients showed no response to L‐dopa or oral dopaminergic medication. They also had optic nerve atrophy of unknown etiology. The severe motor symptoms of both patients were conspicuously alleviated by apomorphine delivered subcutaneously. One patient underwent bilateral subthalamic nucleus deep brain stimulation, which also proved effective. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/F709477DA81BF6273D42B0F7D00924C11109FCA3/fulltext/pdf

DOI: 10.1002/mds.20975

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication</title>
<author><name sortKey="Deutschl Nder, Angela" sort="Deutschl Nder, Angela" uniqKey="Deutschl Nder A" first="Angela" last="Deutschl Nder">Angela Deutschl Nder</name>
</author>
<author><name sortKey="Asmus, Friedrich" sort="Asmus, Friedrich" uniqKey="Asmus F" first="Friedrich" last="Asmus">Friedrich Asmus</name>
</author>
<author><name sortKey="Marelli, Elena" sort="Marelli, Elena" uniqKey="Marelli E" first="Elena" last="Marelli">Elena Marelli</name>
</author>
<author><name sortKey="Klopstock, Thomas" sort="Klopstock, Thomas" uniqKey="Klopstock T" first="Thomas" last="Klopstock">Thomas Klopstock</name>
</author>
<author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
</author>
<author><name sortKey="Botzel, Kai" sort="Botzel, Kai" uniqKey="Botzel K" first="Kai" last="Bötzel">Kai Bötzel</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F709477DA81BF6273D42B0F7D00924C11109FCA3</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20975</idno>
<idno type="url">https://api.istex.fr/document/F709477DA81BF6273D42B0F7D00924C11109FCA3/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003639</idno>
<idno type="wicri:Area/Istex/Curation">003639</idno>
<idno type="wicri:Area/Istex/Checkpoint">001F01</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Deutschl Nder A:excellent:response:to</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16755578</idno>
<idno type="wicri:Area/PubMed/Corpus">002C17</idno>
<idno type="wicri:Area/PubMed/Curation">002C17</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D32</idno>
<idno type="wicri:Area/Ncbi/Merge">001717</idno>
<idno type="wicri:Area/Ncbi/Curation">001717</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001717</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Deutschl Nder A:excellent:response:to</idno>
<idno type="wicri:Area/Main/Merge">004755</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0518119</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001977</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001344</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001B03</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Deutschl Nder A:excellent:response:to</idno>
<idno type="wicri:Area/Main/Merge">004B98</idno>
<idno type="wicri:Area/Main/Curation">003441</idno>
<idno type="wicri:Area/Main/Exploration">003441</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication</title>
<author><name sortKey="Deutschl Nder, Angela" sort="Deutschl Nder, Angela" uniqKey="Deutschl Nder A" first="Angela" last="Deutschl Nder">Angela Deutschl Nder</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Asmus, Friedrich" sort="Asmus, Friedrich" uniqKey="Asmus F" first="Friedrich" last="Asmus">Friedrich Asmus</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurodegenerative Diseases, Hertie‐Institute for Clinical Brain Research, University of Tübingen</wicri:regionArea>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marelli, Elena" sort="Marelli, Elena" uniqKey="Marelli E" first="Elena" last="Marelli">Elena Marelli</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Klopstock, Thomas" sort="Klopstock, Thomas" uniqKey="Klopstock T" first="Thomas" last="Klopstock">Thomas Klopstock</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurodegenerative Diseases, Hertie‐Institute for Clinical Brain Research, University of Tübingen</wicri:regionArea>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
<wicri:noRegion>University of Tübingen</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Botzel, Kai" sort="Botzel, Kai" uniqKey="Botzel K" first="Kai" last="Bötzel">Kai Bötzel</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Grosshadern, Ludwig‐Maximilians University, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-09">2006-09</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1523">1523</biblScope>
<biblScope unit="page" to="1525">1525</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">F709477DA81BF6273D42B0F7D00924C11109FCA3</idno>
<idno type="DOI">10.1002/mds.20975</idno>
<idno type="ArticleID">MDS20975</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Amantadine (administration & dosage)</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Apomorphine (administration & dosage)</term>
<term>Chemotherapy</term>
<term>Combined Modality Therapy</term>
<term>Deep Brain Stimulation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Resistance</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Hypokinesia (diagnosis)</term>
<term>Hypokinesia (drug therapy)</term>
<term>Infusions, Intravenous</term>
<term>Injections, Subcutaneous</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neurologic Examination (drug effects)</term>
<term>Optic Atrophy (diagnosis)</term>
<term>Optic Atrophy (drug therapy)</term>
<term>Optic ataxia</term>
<term>Optic nerve</term>
<term>Optic neuropathy</term>
<term>Oral administration</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinsonism</term>
<term>apomorphine</term>
<term>levodopa</term>
<term>optic nerve neuropathy</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Amantadine</term>
<term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hypokinesia</term>
<term>Optic Atrophy</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypokinesia</term>
<term>Optic Atrophy</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Combined Modality Therapy</term>
<term>Deep Brain Stimulation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Resistance</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Injections, Subcutaneous</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Apomorphine</term>
<term>Ataxie optique</term>
<term>Chimiothérapie</term>
<term>Lévodopa</term>
<term>Nerf optique</term>
<term>Neuropathie nerf optique</term>
<term>Neuropathie optique</term>
<term>Parkinsonisme</term>
<term>Système nerveux pathologie</term>
<term>Voie orale</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Two patients presented with the cardinal symptoms of Parkinson's disease (PD), which had developed slowly and progressively. One patient underwent brain imaging of the dopaminergic system, the results of which were compatible with PD. However, both patients showed no response to L‐dopa or oral dopaminergic medication. They also had optic nerve atrophy of unknown etiology. The severe motor symptoms of both patients were conspicuously alleviated by apomorphine delivered subcutaneously. One patient underwent bilateral subthalamic nucleus deep brain stimulation, which also proved effective. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Bavière</li>
<li>District de Haute-Bavière</li>
</region>
<settlement><li>Munich</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Bavière"><name sortKey="Deutschl Nder, Angela" sort="Deutschl Nder, Angela" uniqKey="Deutschl Nder A" first="Angela" last="Deutschl Nder">Angela Deutschl Nder</name>
</region>
<name sortKey="Asmus, Friedrich" sort="Asmus, Friedrich" uniqKey="Asmus F" first="Friedrich" last="Asmus">Friedrich Asmus</name>
<name sortKey="Botzel, Kai" sort="Botzel, Kai" uniqKey="Botzel K" first="Kai" last="Bötzel">Kai Bötzel</name>
<name sortKey="Gasser, Thomas" sort="Gasser, Thomas" uniqKey="Gasser T" first="Thomas" last="Gasser">Thomas Gasser</name>
<name sortKey="Klopstock, Thomas" sort="Klopstock, Thomas" uniqKey="Klopstock T" first="Thomas" last="Klopstock">Thomas Klopstock</name>
<name sortKey="Marelli, Elena" sort="Marelli, Elena" uniqKey="Marelli E" first="Elena" last="Marelli">Elena Marelli</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003441 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003441 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F709477DA81BF6273D42B0F7D00924C11109FCA3
   |texte=   Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication

Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.